We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.
User:Carson Powers/Sandbox 1
From Proteopedia
(Difference between revisions)
| Line 31: | Line 31: | ||
==AHB2== | ==AHB2== | ||
| - | <scene name='10/1076041/Ahb2_only/3'>AHB2</scene> is a stable miniprotein inhibitor that competes with the ACE2 receptor. It was developed using the Rosetta blueprint builder that incorporates the alpha helix in ACE2 (residues 23-46) into small, stable protein scaffolds. This molecule utilizes van der Waals interactions in its <scene name='10/1076041/Ahb2_stabilizing_vdw/2'>hydrophobic core</scene> to stabilize. <scene name='10/1076041/Ahb2_interactions/1'>Along with making similar interactions with the spike protein, AHB2 includes additional interactions to increase its affinity.</scene> This allows it to compete with the ACE2 receptor effectively, preventing it from binding with the spike protein | + | <scene name='10/1076041/Ahb2_only/3'>AHB2</scene> is a stable miniprotein inhibitor that competes with the ACE2 receptor. It was developed using the Rosetta blueprint builder that incorporates the alpha helix in ACE2 (residues 23-46) into small, stable protein scaffolds. This molecule utilizes van der Waals interactions in its <scene name='10/1076041/Ahb2_stabilizing_vdw/2'>hydrophobic core</scene> to stabilize. <scene name='10/1076041/Ahb2_interactions/1'>Along with making similar interactions with the spike protein, AHB2 includes additional interactions to increase its affinity.</scene> This allows it to compete with the ACE2 receptor effectively, preventing it from binding with the spike protein. |
| - | == | + | ==LCBs== |
<scene name='10/1076042/Overall_lcb1_spike/3'>LCB1</scene> is a fully synthetic three-helix mini protein that acts as a competitive inhibitor, competing with ACE2 to bind to the spike protein. Unlike ABH2, <scene name='10/1076041/Lcb1_interactions/2'>a de novo design approach was taken to design LCB1, making it more compact with optimal interactions with the RBD.</scene> | <scene name='10/1076042/Overall_lcb1_spike/3'>LCB1</scene> is a fully synthetic three-helix mini protein that acts as a competitive inhibitor, competing with ACE2 to bind to the spike protein. Unlike ABH2, <scene name='10/1076041/Lcb1_interactions/2'>a de novo design approach was taken to design LCB1, making it more compact with optimal interactions with the RBD.</scene> | ||
Revision as of 14:06, 15 April 2025
De novo miniprotein Covid therapeutic
| |||||||||||
